Literature DB >> 23169244

Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease.

Dennis Dong Hwan Kim1, Jina Yun, Hong-Hee Won, Lu Cheng, Jie Su, Wei Xu, Jieun Uhm, Vikas Gupta, John Kuruvilla, Hans A Messner, Jeffrey H Lipton.   

Abstract

BACKGROUND: We aimed to develop multiple single-nucleotide polymorphism (SNP)-based risk models associated with the risk of transplant outcomes including graft-versus-host disease (GVHD).
METHODS: The study evaluated 259 SNPs in 53 genes in 394 pairs of donors and recipients. In a discovery set (n=307 receiving related donor transplantation), overall survival, relapse-free survival (RFS), nonrelapse mortality, and acute or chronic GVHD were evaluated.
RESULTS: Eight recipients' SNPs of IL2, IL6R, FAS, EDN1, TGFB1, and NFKBIA genes and 12 donors' SNPs of NOS1, IL1B, TGFB2, NOD2/CARD15, TNFRII, IL1R1, and FCGR2A genes were identified in univariate analyses. Risk models were generated using significant clinical variables and genetic SNP markers after filtering out through multivariate analyses. Then, we divided patients into four quartiles (25%, Q) according to their risks. The final models stratified patients into low-risk (Q1), moderate-risk (Q2, Q3), and high-risk (Q4) groups in terms of overall survival (P<0.0001), RFS (P<0.0001), nonrelapse mortality (P=0.0043), and acute GVHD (P<0.0001), but not for chronic GVHD (P=0.763). External validation was performed in 87 transplant pairs that received matched unrelated donor transplantation, especially for RFS (P=0.016) and acute GVHD (P=0.027).
CONCLUSION: Risk models can improve prognostic stratification of patients according to their risk for transplant outcome.

Entities:  

Mesh:

Year:  2012        PMID: 23169244     DOI: 10.1097/TP.0b013e3182708e7c

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

1.  A pilot study of single nucleotide polymorphisms in the interleukin-6 receptor and their effects on pre- and post-transplant serum mediator level and outcome after allogeneic stem cell transplantation.

Authors:  T H A Tvedt; R Hovland; G Tsykunova; A B Ahmed; T Gedde-Dahl; Ø Bruserud
Journal:  Clin Exp Immunol       Date:  2018-04-01       Impact factor: 4.330

2.  Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.

Authors:  Ezgi Karaesmen; Abbas A Rizvi; Leah M Preus; Philip L McCarthy; Marcelo C Pasquini; Kenan Onel; Xiaochun Zhu; Stephen Spellman; Christopher A Haiman; Daniel O Stram; Loreall Pooler; Xin Sheng; Qianqian Zhu; Li Yan; Qian Liu; Qiang Hu; Amy Webb; Guy Brock; Alyssa I Clay-Gilmour; Sebastiano Battaglia; David Tritchler; Song Liu; Theresa Hahn; Lara E Sucheston-Campbell
Journal:  Blood       Date:  2017-08-15       Impact factor: 22.113

3.  Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD.

Authors:  N Alam; W Xu; E G Atenafu; J Uhm; M Seftel; V Gupta; J Kuruvilla; J H Lipton; H A Messner; D D H Kim
Journal:  Bone Marrow Transplant       Date:  2015-03-16       Impact factor: 5.483

4.  A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.

Authors:  Carolina Martínez-Laperche; Elena Buces; M Carmen Aguilera-Morillo; Antoni Picornell; Milagros González-Rivera; Rosa Lillo; Nazly Santos; Beatriz Martín-Antonio; Vicent Guillem; José B Nieto; Marcos González; Rafael de la Cámara; Salut Brunet; Antonio Jiménez-Velasco; Ildefonso Espigado; Carlos Vallejo; Antonia Sampol; José María Bellón; David Serrano; Mi Kwon; Jorge Gayoso; Pascual Balsalobre; Álvaro Urbano-Izpizua; Carlos Solano; David Gallardo; José Luis Díez-Martín; Juan Romo; Ismael Buño
Journal:  Blood Adv       Date:  2018-07-24

5.  Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models.

Authors:  D Kim; H-H Won; S Su; L Cheng; W Xu; N Hamad; J Uhm; V Gupta; J Kuruvilla; H A Messner; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2014-03-03       Impact factor: 5.483

6.  Replication of associations between genetic polymorphisms and chronic graft-versus-host disease.

Authors:  Paul J Martin; Wenhong Fan; Barry E Storer; David M Levine; Lue Ping Zhao; Edus H Warren; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; Michael Boeckh; Sangeeta Hingorani; Li Yan; Qiang Hu; Leah Preus; Song Liu; Stephen Spellman; Xiaochun Zhu; Marcelo Pasquini; Philip McCarthy; Daniel Stram; Xin Sheng; Loreall Pooler; Christopher A Haiman; Lara Sucheston-Campbell; Theresa Hahn; John A Hansen
Journal:  Blood       Date:  2016-10-06       Impact factor: 22.113

7.  Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors.

Authors:  Esteban Arrieta-Bolaños; Neema P Mayor; Steven G E Marsh; J Alejandro Madrigal; Jane F Apperley; Keiren Kirkland; Stephen Mackinnon; David I Marks; Grant McQuaker; Julia Perry; Michael N Potter; Nigel H Russell; Kirsty Thomson; Bronwen E Shaw
Journal:  Haematologica       Date:  2015-11-26       Impact factor: 9.941

Review 8.  Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?

Authors:  Lara E Sucheston-Campbell; Alyssa Clay; Philip L McCarthy; Qianqian Zhu; Leah Preus; Marcelo Pasquini; Kenan Onel; Theresa Hahn
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

9.  Investigation of TGFB1 -1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation.

Authors:  Petra Kövy; Nóra Meggyesi; Lívia Varga; Katalin Balassa; András Bors; László Gopcsa; Melinda Paksi; Árpád Bátai; Eszter Vad; János Sinkó; Attila Tordai; Tamás Masszi; Péter Reményi; Hajnalka Andrikovics
Journal:  Bone Marrow Transplant       Date:  2019-09-16       Impact factor: 5.483

10.  Genetic susceptibility to acute graft versus host disease in pediatric patients undergoing HSCT.

Authors:  Marc Ansari; Kateryna Petrykey; Mohamed Aziz Rezgui; Veronica Del Vecchio; Jacques Cortyl; Milad Ameur; Tiago Nava; Patrick Beaulieu; Pascal St-Onge; Simona Jurkovic Mlakar; Chakradhara Rao S Uppugunduri; Yves Théoret; Imke H Bartelink; Jaap-Jan Boelens; Robbert G M Bredius; Jean-Hugues Dalle; Victor Lewis; Bill S Kangarloo; Selim Corbacioglu; Daniel Sinnett; Henrique Bittencourt; Maja Krajinovic
Journal:  Bone Marrow Transplant       Date:  2021-07-02       Impact factor: 5.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.